Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 467,760 | 412,612 | 352,299 | 553,074 | 641,755 |
| Marketable Securities | N/A | N/A | N/A | N/A | 60,358 |
| Receivables | 366,221 | 264,926 | 206,442 | 7,727 | 10,103 |
| Inventories | 142,556 | 81,404 | 146,362 | 85,714 | 16,286 |
| Other current assets | 0 | 0 | 22,408 | 36,658 | 70,677 |
| TOTAL | $1,014,840 | $788,954 | $766,331 | $719,523 | $824,047 |
| Non-Current Assets | |||||
| PPE Net | 1,708 | 2,952 | 4,345 | 6,148 | 6,177 |
| Other Non-Current Assets | 58,709 | 93,145 | 18,054 | 34,546 | 51,541 |
| TOTAL | $60,417 | $96,097 | $22,399 | $40,694 | $57,718 |
| Total Assets | $1,075,257 | $885,051 | $788,730 | $760,217 | $881,765 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 93,662 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 56,798 | 38,572 | 37,516 | 37,342 | 16,909 |
| Accrued Expenses | 166,049 | 140,184 | 127,806 | 95,139 | 103,239 |
| Other current liabilities | N/A | N/A | 75,830 | 29,504 | 7,584 |
| TOTAL | $323,596 | $185,509 | $247,593 | $167,610 | $131,847 |
| Non-Current Liabilities | |||||
| Long Term Debt | 361,664 | 359,489 | N/A | N/A | N/A |
| Other Non-Current Liabilities | 19,850 | 111,514 | 346,616 | 422,735 | 551,256 |
| TOTAL | $381,514 | $471,003 | $346,616 | $422,735 | $551,256 |
| Total Liabilities | $705,110 | $656,512 | $594,209 | $590,345 | $683,103 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 127,830 | 125,516 | 120,582 | 111,291 | 97,731 |
| Common Shares | 12 | 12 | 12 | 11 | 10 |
| Retained earnings | -3,012,978 | -3,035,366 | -2,837,488 | -2,308,860 | -1,656,688 |
| Other shareholders' equity | -2,103 | -3,308 | -3,542 | -875 | -2,090 |
| TOTAL | $370,147 | $228,539 | $194,521 | $169,872 | $198,662 |
| Total Liabilities And Equity | $1,075,257 | $885,051 | $788,730 | $760,217 | $881,765 |